Cargando…

Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin

Burkitt’s lymphoma (BL) is a highly aggressive malignancy molecularly characterized by deregulation of the C-MYC proto-oncogene. Recently, it has been confirmed that phosphatidylinositol-3-kinase (PI3K) pathway activation is a crucial element in the malignant transformation of the B cells in BL. Des...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Fan, Huang, Xianbo, Chen, Zhenzhen, Qian, Wenbin, Tong, Xiangmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820316/ https://www.ncbi.nlm.nih.gov/pubmed/29463831 http://dx.doi.org/10.1038/s41598-018-21570-z

Ejemplares similares

β-Hydroxyisovaleryl-Shikonin Exerts an Antitumor Effect on Pancreatic Cancer Through the PI3K/AKT Signaling Pathway
por: Zeng, Yu, et al.
Publicado: (2022)

Matrine exerts antitumor activity in cervical cancer by protective autophagy via the Akt/mTOR pathway in vitro and in vivo
por: Zhang, Fan, et al.
Publicado: (2022)

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
por: Bhatti, Maria, et al.
Publicado: (2018)

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011)

Shikonin overcomes drug resistance and induces necroptosis by regulating the miR-92a-1-5p/MLKL axis in chronic myeloid leukemia
por: Huang, Xianbo, et al.
Publicado: (2020)

β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling
por: LU, DAN, et al.
Publicado: (2015)

β-Hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling
por: Lu, Dan, et al.
Publicado: (2021)

Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway
por: Liu, Suqing, et al.
Publicado: (2022)

Shikonin Derivatives from Onsoma visianii Decrease Expression of Phosphorylated STAT3 in Leukemia Cells and Exert Antitumor Activity
por: Todorovic, Zeljko, et al.
Publicado: (2021)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022)

Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling
por: Dai, Ninggao, et al.
Publicado: (2018)

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
por: Babichev, Yael, et al.
Publicado: (2016)

RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway
por: Jiao, Yuheng, et al.
Publicado: (2022)

Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway
por: Shen, Zhiyong, et al.
Publicado: (2022)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

DHODH Inhibition Exerts Synergistic Therapeutic Effect with Cisplatin to Induce Ferroptosis in Cervical Cancer through Regulating mTOR Pathway
por: Jiang, Mengying, et al.
Publicado: (2023)

Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation
por: De Falco, Giulia, et al.
Publicado: (2015)

Integration of Different “-omics” Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells
por: Wiench, Benjamin, et al.
Publicado: (2013)

Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway
por: Huang, Caimei, et al.
Publicado: (2018)

Promotion of Ovarian Follicle Growth following mTOR Activation: Synergistic Effects of AKT Stimulators
por: Cheng, Yuan, et al.
Publicado: (2015)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
por: Li, Jie, et al.
Publicado: (2019)

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2021)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines
por: Mahbub, AA, et al.
Publicado: (2015)

Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
por: Shi, Wei, et al.
Publicado: (2021)

Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells
por: El-Gowily, Afnan H., et al.
Publicado: (2021)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma
por: Seitz, Volkhard, et al.
Publicado: (2011)

Alteration of MicroRNAs Regulated by c-Myc in Burkitt Lymphoma
por: Onnis, Anna, et al.
Publicado: (2010)

Developments in Burkitt’s lymphoma: novel cooperations in oncogenic MYC signaling
por: Spender, Lindsay C, et al.
Publicado: (2014)

Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases
por: Mundo, Lucia, et al.
Publicado: (2019)

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death
por: Leibowitz, Brian J., et al.
Publicado: (2023)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Shikonin in Colon Cancer
por: Chen, Yang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2l3glj0u7n7m8c52td4bcrd212